Segall Bryant & Hamill LLC Invests $649,000 in Omnicell, Inc. (NASDAQ:OMCL)

Segall Bryant & Hamill LLC acquired a new stake in Omnicell, Inc. (NASDAQ:OMCL) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 14,585 shares of the company’s stock, valued at approximately $649,000.

Several other institutional investors also recently bought and sold shares of the company. Intech Investment Management LLC purchased a new stake in shares of Omnicell in the third quarter valued at about $753,000. Charles Schwab Investment Management Inc. lifted its position in Omnicell by 3.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 594,996 shares of the company’s stock valued at $25,942,000 after purchasing an additional 22,198 shares during the period. The Manufacturers Life Insurance Company boosted its holdings in Omnicell by 7.7% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 25,272 shares of the company’s stock valued at $1,102,000 after purchasing an additional 1,813 shares in the last quarter. PEAK6 Investments LLC purchased a new stake in Omnicell in the 3rd quarter valued at approximately $448,000. Finally, Martingale Asset Management L P acquired a new position in Omnicell during the 3rd quarter worth approximately $507,000. 97.70% of the stock is owned by institutional investors and hedge funds.

Omnicell Stock Performance

NASDAQ:OMCL opened at $35.01 on Friday. Omnicell, Inc. has a twelve month low of $25.12 and a twelve month high of $55.75. The company has a market capitalization of $1.64 billion, a P/E ratio of 129.67, a price-to-earnings-growth ratio of 7.53 and a beta of 0.85. The company has a current ratio of 1.37, a quick ratio of 1.22 and a debt-to-equity ratio of 0.13. The firm has a 50-day moving average price of $39.01 and a two-hundred day moving average price of $42.58.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings data on Thursday, February 6th. The company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. As a group, research analysts expect that Omnicell, Inc. will post 1.09 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently weighed in on OMCL. Wells Fargo & Company decreased their price target on Omnicell from $49.00 to $40.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. Bank of America lowered their price target on shares of Omnicell from $54.00 to $46.00 and set a “neutral” rating on the stock in a research note on Monday, January 6th. StockNews.com cut shares of Omnicell from a “buy” rating to a “hold” rating in a research note on Monday, March 24th. Benchmark restated a “buy” rating and set a $62.00 target price on shares of Omnicell in a research report on Tuesday, February 4th. Finally, JPMorgan Chase & Co. dropped their target price on shares of Omnicell from $44.00 to $36.00 and set a “neutral” rating for the company in a report on Thursday, March 20th. Five analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $51.00.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.